Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pertussis vaccine (Butantan Foundation)
- Development stage
- Unknown
- Lead developer
- Butantan Foundation
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The pertussis vaccine candidate from the Butantan Foundation is a recombinant acellular vaccine (r-aP) developed to provide protection against *Bordetella pertussis*, the bacterium responsible for whooping cough. A distinguishing feature of this candidate is the use of a genetically inactivated pertussis toxin (PT), typically featuring the 9K/129G mutations. This genetic detoxification method preserves the protein's natural conformational epitopes and immunogenicity more effectively than traditional chemical detoxification (e.g., using formaldehyde), while completely eliminating enzymatic toxicity. The vaccine is intended to serve as a safer, highly immunogenic, and cost-effective alternative to whole-cell vaccines, particularly for use as a booster in adolescents and adults or as part of a primary immunization series in infants.
- Other names
- Vacina Pertussis acelularrecombinant acellular pertussis vaccineButantan pertussis vaccine
Beyond the preview
Go deeper on pertussis vaccine (Butantan Foundation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pertussis vaccine (Butantan Foundation).